Literature DB >> 6333283

Inhibition of interleukin-2-dependent cytotoxic T-lymphocyte growth by gangliosides.

W D Merritt, J M Bailey, D H Pluznik.   

Abstract

Previous work has shown that exogenous gangliosides suppress lectin-induced T-lymphocyte mitogenesis in mixed populations of immune cells. As one potential cellular site of this inhibition, the influence of gangliosides on interleukin-2-dependent T-cell proliferation was tested, using cultures of cytotoxic T cells (strain CT-6). Incubation of CT-6 cells with mixed bovine brain gangliosides resulted in a dose-dependent inhibition of cell proliferation. Cell viability was unaffected by gangliosides, and the inhibition was totally reversed when the gangliosides were removed. Individual purified gangliosides were tested and GM2 was most inhibitory (I50 = 15 microM). GD1a and GT1b were somewhat less potent, whereas GM1 and GM3 were only weakly inhibitory. Various nonpolar lipids, sulfatides, and sialic acid did not inhibit CT-6 cell growth. The results suggest that a primary mechanism whereby gangliosides inhibit lectin-induced lymphocyte mitogenesis is by inhibition of the interleukin-2-stimulated proliferation of T cells in these cultures.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333283     DOI: 10.1016/0008-8749(84)90191-6

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  Effects of ganglioside (Cronassial) treatment on MHC Ia antigen expression and allograft survival of pancreatic islets in diabetic rats.

Authors:  R G Bretzel; B K Flesch; J Willig; M Woehrle; K Federlin
Journal:  Diabetologia       Date:  1990-02       Impact factor: 10.122

2.  Activation of human T lymphocytes by ganglioside-containing liposomes.

Authors:  K Yanagihara; E Kato; S Hitomi; J Sunamoto; H Wada
Journal:  Glycoconj J       Date:  1999-01       Impact factor: 2.916

3.  Gangliosides shed by tumor cells enhance tumor formation in mice.

Authors:  S Ladisch; S Kitada; E F Hays
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

Review 4.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

5.  Potentiation of interleukin-2 production and its binding by monoclonal antibodies to the gangliosides GD3 and GD2.

Authors:  S Schibeci; P Hersey; D Cheresh
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 6.  Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.

Authors:  Andrea Gras Navarro; Andreas T Björklund; Martha Chekenya
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.